Pharmacotherapy of pulmonary hypertension (according to the 2015 ESC/EAS Guidelines for the diagnosis and treatment of pulmonary hypertension)
https://doi.org/10.20996/1819-6446-2016-12-1-79-86
Abstract
Indications and efficacy of drugs used for the treatment of pulmonary hypertension are considered. Stages of the treatment of pulmonary arterial hypertension are discussed, including maintenance therapy, specific therapy with calcium channel blockers, prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin agonists, guanylate cyclase stimulators, combination treatment.
About the Authors
E. L. Trisvetova
Belarusian State Medical University. Prospect Dzerzhinskogo 83, Minsk, 220116 Belorussia
Russian Federation
Russian Federation
S. V. Gubkin
Belarusian State Medical University. Prospect Dzerzhinskogo 83, Minsk, 220116 Belorussia
Russian Federation
Russian Federation
References
1. Galiè N., Humbert M., Jean-Luc Vachiery J-L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016;37(1):67-119.
2. Chazova IE, Avdeev SN, Tsareva NA, et al. Clinical guidelines for diagnosis and treatment of pulmonary hypertension. TerapevticheskiĭArkhiv 2014; 9: 4-23. In Russian (Чазова И.Е., Авдеев С.Н., Царева Н.А., и др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевтический Архив 2014; 9:4-23).
3. Herve P., Humbert M., Sitbon O., et al. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin Chest Med 2001;22:451-8.
4. Fuster V., Steele P.M., Edwards W.D., et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
5. Preston IR, Roberts KE, Miller DP Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation 2015;132(25):2403-11.
6. Chazova IE, Cherniavsky AM, Martyniuk T., et al. Topical issues of chronic thromboembolic pulmonary hypertension: the advice of experts. Kardiologicheskiy Vestnik 2015; 1: 78-9. In Russian (Чазова И.Е., Чернявский А.М., Мартынюк Т.В., и др. Актуальные вопросы хронической тромбоэмболической легочной гипертензии: мнение экспертов. Кардиологический Вестник 2015;1:78-9).
7. Cohn J.N. Optimal diuretic therapy for heart failure. Am J Med 2001;111(7):577.
8. Hosenpud J.D., Greenberg В.Н. Congestive Heart Failure. Lippincott: Williams & Wilkins, Philadelphia; 2007.
9. Mareev VY, Ageev FT, Arutyunov GP, et al. National guidelines PRAs, RKO and RNMOT for diagnosis and treatment of chronic heart failure (fourth revision). Serdechnaya Nedostatochnost' 2013; 7 (81): 379-472. In Russian (Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная Недостаточность 2013;7 (81):379-472).
10. Weitzenblum E., Sautegeau A., Ehrhart M., et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131:493-8.
11. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-92.
12. Ruiter G., Lankhorst S., Boonstra A., et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011;37:1386-91.
13. Broberg C.S., Bax B.E., Okonko D.O., et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006;48:356-65.
14. Sitbon O., Humbert M., Jaı¨s X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-111.
15. Tonelli A.R., Alnuaimat H., Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010;104(4):481-96.
16. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [see comments]. N Engl J Med 1992;327:76-81.
17. Galie N., Hoeper M.M., HumbertM. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
18. Rich J., Thenappan T., Murphy D., O’Callaghan D.S. From endothelial progenitor cells to vascular remodelling and more: 6 months in pulmonary hypertension. Int J Clin Pract 2007;61(Suppl 158):26-36.
19. Montani D., Savale L., Natali D., et al. Long-term response to calcium-channel blockers in nonidiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:1898-907.
20. Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-37.
21. Galie N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, doubleblind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-9.
22. Galie` N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008;371:2093-100.
23. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. New Eng J Med 2002;346:896-903.
24. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9.
25. Gatzoulis M.A., Beghetti M., Galiè N., et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. Int J Cardiol 2008;127:27-32.
26. Lee Y.H., Song G.G. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension. Korean J Intern Med 2013: 28(6):701-7.
27. Pulido T., Adzerikho I., Channick R.N., et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369:809-18.
28. Sidcharta P.N., Krähenbühl S., Dingemanse J. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2015;11(3):437-449.
29. Galie N., Ghofrani H.A., Torbicki A., et al. The Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
30. Sastry B.K.S, Narasimhan C., Reddy N.K., et al. Clinical efficacy of sildenafil in primary crossover study. J Am Coll Cardiol 2004;43:1149-53.
31. Ghofrani H.A., Galie N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40.
32. Badesch D.B., McLaughlin V.V., Delcroix M., et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12):56S-61S.
33. Galie N., Manes A., Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003;2:123-37.
34. Sitbon O., Delcroix M., Bergot E.,et al. EPITOME-2: an open-label study assessingthe transition to a new formulation of intravenous epoprostenol in p atients with pulmonary arterial hypertension. Am Heart J 2014;167:210-7.
35. Hoeper M., Leuchte H., Halank M., et al. Combining inhaled iloprostwith bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;4:691-4.
36. Simonneau G., Torbicki A., Hoeper M.M,et al. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012;40:874-80.
37. Kuwano K., Hashino A., Noda K., et al. A longacting and highly selective prostacyclin receptor agonist prodrug, 2-[4-[(5,6-diphenyl pyrazin-2-yl) (isopropyl) amino] butoxy]-N-(methylsulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, [4-[(5,6-diphenylpyrazin-2-yl) (isopropyl) amino] butoxy ]acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008; 326: 691-9.
38. Galie N., Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J Am Coll Cardiol 2013;62:1101-2.
39. Sitbon O., Jaïs X., Savale L., et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014;43:1691-7.
40. Galie N., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31:2080-6.
41. Nickel N., Golpon H., Greer M., et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012;39:589-6.
Review
For citations:
Trisvetova E.L., Gubkin S.V. Pharmacotherapy of pulmonary hypertension (according to the 2015 ESC/EAS Guidelines for the diagnosis and treatment of pulmonary hypertension). Rational Pharmacotherapy in Cardiology. 2016;12(1):79-86. https://doi.org/10.20996/1819-6446-2016-12-1-79-86
Views:
927
Email this article 